Noreen Henig - Jul 24, 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Chief Medical Officer
Signature
/s/ Marc Belsky, Attorney-in-Fact
Stock symbol
KZR
Transactions as of
Jul 24, 2023
Transactions value $
$0
Form type
4
Date filed
7/26/2023, 05:02 PM
Previous filing
Jun 20, 2023
Next filing
Jun 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -300K -100% 0 Jul 24, 2023 Common Stock 300K $4.56 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Award +300K 300K Jul 24, 2023 Common Stock 300K $2.28 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -280K -100% 0 Jul 24, 2023 Common Stock 280K $5.45 Direct F2, F3
transaction KZR Employee Stock Option (right to buy) Award +280K 280K Jul 24, 2023 Common Stock 280K $2.28 Direct F2, F3
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -180K -100% 0 Jul 24, 2023 Common Stock 180K $14.55 Direct F2, F4
transaction KZR Employee Stock Option (right to buy) Award +180K 180K Jul 24, 2023 Common Stock 180K $2.28 Direct F2, F4
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -220K -100% 0 Jul 24, 2023 Common Stock 220K $6.84 Direct F2, F5
transaction KZR Employee Stock Option (right to buy) Award +220K 220K Jul 24, 2023 Common Stock 220K $2.28 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vested on May 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
F3 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
F4 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
F5 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.